成人严重感染或脓毒症/脓毒性休克的血液净化:随机对照试验的网络荟萃分析
该网络荟萃分析纳入60项随机对照试验共4595例成人严重感染或脓毒症/脓毒性休克患者,比较16种血液净化模式与17种干预。主要终点总体死亡率方面,多黏菌素B血液灌流(RR 0.70,95%CI 0.57-0.86,证据确定性极低)和血浆置换(RR 0.61,95%CI 0.42-0.91,证据确定性低)与较低死亡率相关。因存在高度临床异质性和不可传递性,多黏菌素B血液灌流的潜在获益仍无定论。次要终点分析受研究数量稀少限制,HA330联合高容量连续性静脉-静脉血液滤过(CVVH)、HA330及标准容量CVVH与更短ICU住院时间相关,并有助于减少机械通气天数,但无干预显著降低急性肾损伤发生率或肾脏替代治疗需求。
要点
- 纳入60项RCT共4595例成人严重感染或脓毒症/脓毒性休克患者,比较16种血液净化模式。
- 血浆置换与较低死亡率相关(RR 0.61,95%CI 0.42-0.91,证据确定性低)。
- 多黏菌素B血液灌流与较低死亡率相关(RR 0.70,95%CI 0.57-0.86,证据确定性极低),但因高度临床异质性和不可传递性,潜在获益仍无定论。
- HA330联合高容量CVVH、HA330及标准容量CVVH与更短ICU住院时间和更少机械通气天数相关。
- 无干预显著降低急性肾损伤发生率或肾脏替代治疗需求;作者认为需进一步RCT确定可能获益的特定患者人群。
适用人群与场景
- 成人严重感染或脓毒症/脓毒性休克患者。
研究设计与关键结果
- 研究类型为系统评价与网络荟萃分析,仅纳入随机对照试验,共60项RCT、4595例参与者,比较16种血液净化模式与17种干预。
- 主要终点总体死亡率:多黏菌素B血液灌流RR 0.70(95%CI 0.57-0.86,证据确定性极低);血浆置换RR 0.61(95%CI 0.42-0.91,证据确定性低)。
- 因存在高度临床异质性和不可传递性,多黏菌素B血液灌流的潜在获益仍无定论。
- 次要终点分析受可用研究稀少限制;HA330联合高容量CVVH、HA330及标准容量CVVH与更短ICU住院时间相关。
- HA330联合高容量CVVH、HA330及标准容量CVVH有助于减少机械通气天数。
- 无干预显示急性肾损伤发生率或肾脏替代治疗需求显著降低。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与网络荟萃分析。
- 证据确定性:多黏菌素B血液灌流为极低确定性证据,血浆置换为低确定性证据。
- 局限:存在高度临床异质性和不可传递性;次要终点分析受可用研究稀少限制;作者指出需进一步RCT确定可能获益的特定患者人群。
对床旁实践的改变
- 作者认为,与单纯标准治疗相比,血浆置换和多黏菌素B血液灌流可能为成人严重感染或脓毒症/脓毒性休克患者提供潜在获益,但多数比较基于低或极低确定性证据。
- 作者指出,多黏菌素B血液灌流的治疗效果仍不确定。
- 作者建议,需进一步RCT确定可能从体外血液净化中获益的特定患者人群。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to conduct a comprehensive and updated systematic review with network meta-analysis (NMA) to assess the outcome benefits of various blood purification modalities for adult patients with severe infection or sepsis.
DATA SOURCES: We conducted a search of PubMed, MEDLINE, clinical trial registries, Cochrane Library, and Embase databases with no language restrictions.
STUDY SELECTION: Only randomized controlled trials (RCTs) were selected.
DATA EXTRACTION: The primary outcome was overall mortality. The secondary outcomes were the length of mechanical ventilation (MV) days and ICU stay, incidence of acute kidney injury (AKI), and kidney replacement therapy requirement.
DATA SYNTHESIS: We included a total of 60 RCTs with 4,595 participants, comparing 16 blood purification modalities with 17 interventions. Polymyxin-B hemoperfusion (relative risk [RR]: 0.70; 95% CI, 0.57-0.86) and plasma exchange (RR: 0.61; 95% CI, 0.42-0.91) were associated with low mortality (very low and low certainty of evidence, respectively). Because of the presence of high clinical heterogeneity and intransitivity, the potential benefit of polymyxin-B hemoperfusion remained inconclusive. The analysis of secondary outcomes was limited by the scarcity of available studies. HA330 with high-volume continuous venovenous hemofiltration (CVVH), HA330, and standard-volume CVVH were associated with shorter ICU stay. HA330 with high-volume CVVH, HA330, and standard-volume CVVH were beneficial in reducing MV days. None of the interventions showed a significant reduction in the incidence of AKI or the need for kidney replacement therapy.
CONCLUSIONS: Our NMA suggests that plasma exchange and polymyxin-B hemoperfusion may provide potential benefits for adult patients with severe infection or sepsis/septic shock when compared with standard care alone, but most comparisons were based on low or very low certainty evidence. The therapeutic effect of polymyxin-B hemoperfusion remains uncertain. Further RCTs are required to identify the specific patient population that may benefit from extracorporeal blood purification.
参考来源
- Chen JJ, Lai PC, Lee TH, et al. Blood Purification for Adult Patients With Severe Infection or Sepsis/Septic Shock: A Network Meta-Analysis of Randomized Controlled Trials. Crit Care Med. 2023. PMID: 37470680. doi:10.1097/CCM.0000000000005991
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。